Prognostic value of pre-chemoradiotherapy pan-immune-inflammation value (PIV) in locally advanced nasopharyngeal cancers

Abstract

Background To examine the prognostic relevance of pan-immune-inflammation value (PIV) in locally advanced nasopharyngeal carcinomas (LA-NPC) patients treated with concurrent chemoradiotherapy (CCRT) definitively. Methods We used receiver operating characteristic (ROC) curve analysis to determine an optimal PIV cutoff that could effectively divide the patient cohort into two distinct groups based on distant metastasis-free (DMFS) and overall survival (OS) results. For this purpose, receiver operating characteristic (ROC) curve analysis was employed. Our primary and secondary endpoints were to investigate the potential correlations between pre-CCRT PIV measurements and post-CCRT OS and DMFS outcomes, respectively. Results This retrospective cohort study included 179 LA-NPC patients. The optimal PIV cutoff was 512 (area under the curve: 74.0%;sensitivity: 70.8%, specificity: 68.6%;J-index: 0.394) in ROC curve analysis, creating two patient groups: Group-1: PIV < 512 (N = 108);vs Group-2: PIV >= 512 (N = 71). In the comparative analysis, although there were no significant differences between the two groups regarding the patient, disease, and treatment characteristics, the PIV >= 512 group had significantly poorer median OS [74.0 months vs not reached yet (NR);HR: 2.81;P < 0.001] and DMFS (27.0 months vs NR;HR: 3.23;P < 0.001) than the PIV < 512 group. Apart from PIV >= 512, the N2-3 nodal stage and >= 5% weight loss within the preceding 6 months were significant predictors of unfavorable outcomes for DMFS (P < 0.05 for each) and OS (P < 0.05 for each) in univariate analyses. The results of the multivariate analysis showed that each of the three variables had independent negative impacts on both DMFS and OS outcomes (P < 0.05 for each). Conclusions The present findings indicate that PIV, which classifies these patients into two groups with significantly different DMFS and OS, might be a potent prognostic biological marker for LA-NPC patients.